Search
Pulmonary Fibrosis Clinical Trials in Wilmington, NC
A listing of 5 Pulmonary Fibrosis clinical trials in Wilmington, NC actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 5 of 5
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Pulmonary Fibrosis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Wilmington, North Carolina, currently has 5 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/05/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/05/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the th... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/28/2025
Locations: PMG Research, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: GSK Investigational Site, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Accellacare, Wilmington, North Carolina
Conditions: Progressive Pulmonary Fibrosis
1 - 5 of 5